Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer

BACKGROUND: New therapeutic options for metastatic pancreatic cancer are urgently needed. In pancreatic cancer, overexpression of the epidermal growth factor receptor 2 (HER2) has been reported in up to 45%. This multicentre phase II study investigated the efficacy and toxicity of the HER2 antibody...

Descripción completa

Detalles Bibliográficos
Autores principales: Harder, J, Ihorst, G, Heinemann, V, Hofheinz, R, Moehler, M, Buechler, P, Kloeppel, G, Röcken, C, Bitzer, M, Boeck, S, Endlicher, E, Reinacher-Schick, A, Schmoor, C, Geissler, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3304403/
https://www.ncbi.nlm.nih.gov/pubmed/22374460
http://dx.doi.org/10.1038/bjc.2012.18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3304403/
https://www.ncbi.nlm.nih.gov/pubmed/22374460
http://dx.doi.org/10.1038/bjc.2012.18

Ejemplares similares